Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

February 20, 2018

Responsive image

HOD HASHARON, Israel, Feb. 20, 2018 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced it has received Institutional Review Board (IRB) approval for the protocol of its…

Category: Precious Metals